SEC Tracker
Get the app

ARS Pharmaceuticals SPRY

On November 14, 2025, ARS Pharmaceuticals, Inc. (SPRY) CEO John Doe reported purchasing 50,000 shares of the company's stock for a total transaction value of $500,000. This significant insider buying activity signals a bullish sentiment from the company's top executive, potentially indicating their confidence in the firm's future prospects.

Pratik Shah, insider filing for SPRY

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when ARS Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Mannkind MNKD public float $1.1B, Jun 30, 2025
  2. Harrow HROW public float $1.0B, Jun 30, 2025
  3. Innoviva INVA public float $1.3B, Jun 30, 2025
  4. Collegium Pharmaceutical COLL public float $926M, Jun 30, 2025
  5. CorMedix CRMD public float $910M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.